CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 e...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Hu, Shimin, Xu-Monette, Zijun Y., Balasubramanyam, Aarthi, Manyam, Ganiraju C., Visco, Carlo, Tzankov, Alexander, Liu, Wei-min, Miranda, Roberto N., Zhang, Li, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., Han van Krieken, J., Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Zhao, Xiaoying, Winter, Jane N., Zhang, Mingzhi, Li, Ling, Møller, Michael B., Piris, Miguel A., Li, Yong, Go, Ronald S., Wu, Lin, Medeiros, L. Jeffrey, Young, Ken H.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2013
נושאים:
Lymphoid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700465/
https://ncbi.nlm.nih.gov/pubmed/23343832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-10-461848
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים